enhancing clinical outcomes in cll through selection of optimal frontline therapy
Published 9 years ago • 234 plays • Length 25:12Download video MP4
Download video MP3
Similar videos
-
13:26
selection of front-line mcl therapies for optimizing outcomes in young vs. old patients
-
4:20
selecting the optimal frontline therapy in cll
-
12:15
challenges of selecting frontline therapy in cll
-
8:16
optimizing frontline therapy selection and follow-up in cll
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
14:21
debate: which is the optimal approach for cll? - fcr
-
27:18
novel treatment options in cll
-
22:08
role of chemotherapy in cll management
-
27:28
risk assessment in cll treatment
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
35:31
cll: btk inhibitors in hematologic oncology pathways - pathway-guided choices
-
21:05
cll: optimal approaches for patients with deletion 17p
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
5:04
targeted therapy options for frontline cll
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
19:04
cll: sequencing decisions using current therapy options
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
24:17
combination of novel agents in cll: is this the final answer?
-
14:48
debate: best frontline regimen for a cll patient aged 60 who requires therapy - ibrutinib